The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Does anyone know why particularly the d2w product but also the wider product range is not getting traction in the UK - as Symphony's home country? Not least the reasonably good awareness of the issues with plastic waste, bread increasingly being offered in paper bags and so on.
Thanks for taking the time to respond TruroTrader.
Not in any way meaning to argue/tell SRT how to do its business but wouldn't just one well put together cold call to UK Gov be worth the investment?
In asking, I'm reflecting on the essential long standing uselessness of the UKGov and Civil Service in identifying good solutions to any sort of meaningful issue. Unless being hit brutally over the head with the solution :)
As an external third party, I am also thinking that SRT's truly excellent technology is somewhat "hidden under a bushel" (no negative reflection on SRT intended) outside the fisheries/navigation sector. And as someone in international business myself, I have certainly experienced some benefit from UKGov getting behind quality British products and raising their profile a bit.
Anyway, just asking here as I haven't had the opportunity to attend any shareholder meetings. But meanwhile am continuing to invest in line with my modest means - in what I think is an excellent company.
Can I ask any LTH's if they can clear up something for me - why haven't SRT been able to secure any major contracts (that I am aware of) with HMGov? Being a UK company and all that and given boatloads of traffic across the Channel and so on. Seems to me there is an open goal there and would help foreign sales - "if your own government won't buy your kit, why would we?..." as well as potentially being logistically easier to deliver on.
The RNS in the second paragraph suggests this funding provides runway to Q4 2024 yet the penultimate paragraph just before General Meeting suggests Q1 2024. The difference is pretty fundamental to SAR I suggest - anyone know the correct dates or able to reconcile the difference?
Does anyone know if PAF will be looking to extract rare earths from the Mintails tailings? Rainbow Rare Earths are working towards doing this with some tailings they have secured in South Africa. Superficially, as well targeting gold, PAF could also look to extract rare earths at the same time, I assume there would be some more complexity to the extraction process but presumably this is not insurmountable and would potentially add a very valuable additional income stream at PAF. Anyone know if this has come at shareholder meetings etc?
As further grist to the mill:
https://www.reuters.com/markets/europe/funds-jump-back-into-copper-betting-chinese-recovery-2023-01-17/#:~:text=LONDON%2C%20Jan%2017%20(Reuters),the%20world%27s%20largest%20metals%20buyer.
Interesting market commentary I read today on the implications of rouble/gold convertibility and the implications for the gold price:
"..the Russians are now only selling gas in roubles, which means Europe must first buy roubles in the foreign exchange markets in order to pay for the gas. This causes a squeeze in the international price of the rouble. And as the rouble is now convertible into gold, every cubic foot of Russian gas Europe consumes puts a bid under the price of gold."
We all know how the Germans and Italians have a huge job to do to wean themselves off Russian gas/oil. Aside from funding the Russian war machine, it seems they might also start funding growth in the gold price.
Does anyone know if in addition to the planned gold recovery from the Blyvoor tailings, Pan African will also target rare earth metals recovery? Rainbow Rare Earths seem to think such tailings, following their Phalaborwa acquisition, present significant opportunity. Might be a nice addition to Pan African's revenue stream.
Thanks ndr.
The protein mapping, as well as DNA/genome mapping was in my mind too, especially when you look at where all these emerging technologies start to overlap/converge.
All of us are aware that most drug discovery is only a few steps ahead of "throwing muck at a wall to see what sticks..." and that many drugs are effectively ill-targeted "sledgehammers used to hit a nut". So if technology can be used to speed up and target promising molecules, so much the better - allowing of course for it being early days with much technology development and refinement still to come.
Whilst noting Thoth's reminder that SAR are not developing new molecules at present in favour of achieving success with their existing portfolio (which I support), I am also looking past that obvious "for now" statement at what longer term strategies might be in SAR's pipeline - particularly if it supports a higher valuation. And in the scenario SAR's existing portfolio does not gain the traction we are all hoping for (low risk of imo but still there as a risk), what will the BOD do next? Go home and give up?
SOG has also picked up another point in my mind - could some of these new technologies outflank SAR? As he notes, SAR has extensive patent protection in place/assumed to be coming. But it seems too early to say that SAR has got all the key molecules in this area covered. Almost every single day there is some new discovery about how the human body actually works, only to then find it is only another "layer of the onion" that has actually been discovered.
For me, as an investor, I would much rather invest in a drug discovery company that has picked some winners "the old way" and then is seeking to enhance its effectiveness in identifying promising molecules with new technologies. Versus investing in the sort of companies that acquire the technology and the ask "what shall we do now....?"
Hello, first time post here. A LTH from around 2003 although up and down with the usual vagaries of life.
Some excellent research and incisive comment on this BB. Thank-you - almost every day I learn some more.
A thought about SAR and AI that I wanted to seek views on. We have all seen how AI is starting to be deployed to speed up the sifting of promising molecules for potential drug development. It seems to me that the AI still has to be pointed in some sort of direction - there are countless molecules out there. SAR seem to be on the track of being able to demonstrate they have been able to pick some molecule "winners" the old way - let's see. Does anyone know if SAR are looking at bringing AI into their work to speed up the identification of promising molecules in the TYK and associated space? With super quick patenting to lock down the IP of course.
If so, this might demonstrate a path to a pipeline more than the 2 to 3 molecules currently in the frame - and a big driver of forward valuation.